In this video, Nancy S. Reau, MD, FAASLD, AGAF, discusses 36-month results from the ongoing phase 3 ASSURE open-label extension trial of Livdelzi in patients with primary biliary cholangitis.“Earlier ...
Guardian US editor in chief Betsy Reed, who previously led The Nation and The Intercept, told me the American outpost of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback